Nxera Pharma Co.,Ltd. [4565.T]
TOKYO, Apr 20 (Pulse News Wire) – Nxera Pharma CO.,LTD. (4565.T) announced today that it has received a milestone payment of approximately $148.9 million from AbbVie Inc.
As part of their drug development collaboration targeting neurological disorders. This marks the third milestone achieved since 2025, demonstrating steady progress in the pipeline.
Under the agreement, Nxera Pharma could potentially earn up to $1.489 billion in additional milestones based on further development and commercial goals, along with tiered royalties tied to global sales. Christopher Kargill, President and CEO of Nxera Pharma, commented, “Achieving this third milestone underscores the productive advancement of our pipeline with AbbVie.
Continued progress across multiple targets validates the partnership’s potential and aligns with our mission to address significant unmet medical needs in neurology.” The impact of this milestone on Nxera Pharma's consolidated performance for the fiscal year ending December 2026 has already been incorporated into the forecast disclosed on February 13, 2026.
🟢 Confidence: High AI-translated content.